Compare Mesoblast Limited (MESO) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Toro Company (The) Common Stock — how do they compare? Mesoblast Limited trades at $13.76 (market cap $1.83B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.27B). The key difference: Toro Company (The) Common Stock is far larger — about 5.1× Mesoblast Limited's market cap, and Toro Company (The) Common Stock pays a 1.59% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Toro Company (The) Common Stock for 0 Days on average.
| MESO | TTC | |
|---|---|---|
Market Cap | $1.83B | $9.27B |
Volume | 259,445 | 688,325 |
Sector | Health | Industrials |
52-Week High | $20.96 | $101.76 |
52-Week Low | $13.19 | $67.99 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $1.91B | $10.17B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
